LIXTE生物技术公司获得Liora技术,将其PP2A抑制剂LB-100与质子疗法相结合,推进综合癌症治疗。 LIXTE Biotechnology acquires Liora Technologies to integrate its PP2A inhibitor LB-100 with proton therapy, advancing combination cancer treatments.

LIXTE生物技术(NASDAQ:LIXT)通过获得Liora技术,正在超越单分子焦点而扩展,并增加了LIGHT系统——一种压缩、低成本质子治疗装置。 LIXTE Biotechnology (NASDAQ:LIXT) is expanding beyond its single-molecule focus by acquiring Liora Technologies, adding the LiGHT System—a compact, lower-cost proton therapy device. 这一举措将药物开发与医疗技术相结合,使LIXTE能够利用其PP2A抑制剂LB-100和辐射处理研究混合疗法。 This move integrates drug development with medical technology, enabling LIXTE to explore combination therapies using its PP2A inhibitor LB-100 and radiation treatment. 通过控制药物和运载系统,该公司旨在通过协同、多式办法加快临床试验和改善癌症护理。 By controlling both the drug and delivery system, the company aims to accelerate clinical trials and improve cancer care through synergistic, multimodal approaches. 战略转变位置LIXTE是一个多样化的肿瘤平台,具有更大的增长潜力。 The strategic shift positions LIXTE as a diversified oncology platform with enhanced growth potential.